Precision medicine has revolutionized the landscape of neurological care, shifting from “one-size-fits-all” approaches to ...

Valencia, Spain and New York, January 28, 2025 – Quibim, a healthtech company focused on the use of imaging biomarkers for precision medicine, announced today the close of its $50 million Series A ...

Advanced biliary tract cancer represents one of the most challenging gastrointestinal malignancies in China, with increasing ...

A new research paper was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at ...

Boston, US, and Rolle, Switzerland, September 5, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an ...

The identification and study of inflammation-related biomarkers have emerged as a pivotal area of research, offering new avenues for early diagnosis, prognostic assessment, and targeted therapy in the ...

The MarketWatch News Department was not involved in the creation of this content. TARPON SPRINGS, Fla., September 17, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), ...

Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to ...

At this year's American College of Rheumatology (ACR) annual meeting, researchers highlighted emerging approaches aimed at ...

An overarching goal within modern medicine is to increase efficacy of treatment whilst decreasing off-target effects. In recent years, this has manifested through targeted therapies for many disease ...

SAN DIEGO — In tough-to-treat chronic inflammatory bowel disease (IBD), a precision-medicine strategy based on patients’ molecular profiles showed efficacy in guiding anti–tumor necrosis factor ...

TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing ...